Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Ekso Bionics Holdings (EKSO) Other financing activities (2017 - 2024)

Ekso Bionics Holdings has reported Other financing activities over the past 6 years, most recently at $1000.0 for Q2 2024.

On a quarterly basis, Other financing activities changed 0.0% to $1000.0 in Q2 2024 year-over-year; TTM through Mar 2025 was $1000.0, a 0.0% change, with the full-year FY2024 number at $1000.0, changed N/A from a year prior.
Other financing activities reached $1000.0 in Q2 2024 per EKSO's latest filing, roughly flat from $1000.0 in the prior quarter.
The five-year high for Other financing activities was $1000.0 in Q2 2023, with the low at $1000.0 in Q2 2023.